Kontroversi Penggunaan SSRI pada Premenstrual Syndrome dan Premenstrual Dysphoric Disorder

Oleh :

dr.Tommy Raharja, Sp.KJ

Selective serotonin reuptake inhibitors (SSRI) telah disetujui penggunaannya untuk penatalaksanaan premenstrual syndrome (PMS) dan premenstrual dysphoric disorder (PMDD). Golongan SSRI dapat diberikan pada fase luteal maupun secara kontinu. Meski demikian, masih banyak kontroversi terkait penggunaan SSRI pada kasus PMS dan PMDD, terutama karena golongan ini membawa risiko efek samping serius seperti sindrom serotonin.[1-3]

Perbedaan Premenstrual Syndrome dan Premenstrual Dysphoric Disorder

Premenstrual syndrome (PMS) mencakup manifestasi somatik dan psikologis yang signifikan secara klinis selama fase luteal siklus menstruasi. Manifestasi ini akan hilang dalam beberapa hari setelah menstruasi. Sekitar 20% perempuan mengalami gejala yang berat hingga mengganggu aktivitas, dan sisanya mengalami gejala ringan-sedang. Gejala PMS dapat berupa perubahan nafsu makan, nyeri perut dan pinggang, sakit kepala, pembengkakan dan nyeri payudara, gelisah, mudah tersinggung, dan perubahan suasana hati.[1-3]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Gudipally PR, Sharma GK. Premenstrual Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. https://www.ncbi.nlm.nih.gov/books/NBK560698/
2. Tiranini L, Nappi RE. Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Fac Rev. 2022 Apr 28;11:11. doi: 10.12703/r/11-11.
3. Oboza P, Ogarek N, Wójtowicz M, Rhaiem TB, Olszanecka-Glinianowicz M, Kocełak P. Relationships between Premenstrual Syndrome (PMS) and Diet Composition, Dietary Patterns and Eating Behaviors. Nutrients. 2024; 16(12):1911. doi: 10.3390/nu16121911.
4. Jespersen C, Lauritsen MP, Frokjaer VG, Schroll JB. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. Cochrane Database of Systematic Reviews 2024, Issue 8. Art. No.: CD001396. DOI: 10.1002/14651858.CD001396.pub4.
5. Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. https://www.ncbi.nlm.nih.gov/books/NBK554406/
6. Miller KN, Standeven L, Morrow AL, Payne JL, Epperson CN, Hantsoo L. GABAergic neuroactive steroid response to sertraline in premenstrual dysphoric disorder. Psychoneuroendocrinology. 2024 Feb;160:106684. doi: 10.1016/j.psyneuen.2023.106684.
7. Reilly TJ, Wallman P, Clark I, Knox CL, Craig MC, Taylor D. Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials. J Psychopharmacol. 2023 Mar;37(3):261-267. doi: 10.1177/02698811221099645.
8. Maranho MCMF, Guapo VG, de Rezende MG, Vieira CS, Brandão ML, Graeff FG, Lovick T, Del-Ben CM. Low doses of fluoxetine for the treatment of emotional premenstrual syndrome: a randomized double-blind, placebo-controlled, pilot study. Psychoneuroendocrinology. 2023; 157:106360. doi: 10.1016/j.psyneuen.2023.106360.
9. Carlini SV, Deligiannidis KM. Evidence-Based Treatment of Premenstrual Dysphoric Disorder: A Concise Review. J Clin Psychiatry. 2020 Feb 4;81(2):19ac13071. doi: 10.4088/JCP.19ac13071.
10. Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, Kaye AD, Viswanath O, Urits I, Boyer AG, Cornett EM, Kaye AM. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021 Aug 5;13(3):387-401. doi: 10.3390/neurolint13030038.
11. Naguy A, El-Sheshai A, Thiguti SH, Alamiri B. Psychopharmacotherapy of Premenstrual Dysphoric Disorder-New Vistas. Psychopharmacol Bull. 2022 Jun 27;52(3):81-83.
12. Varkey B. Principles of Clinical Ethics and Their Application to Practice. Med Princ Pract. 2021;30(1):17-28. doi: 10.1159/000509119.